Literature DB >> 11848729

Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s.

Peter D Weinberg1, Jennie Hounshell, Laurence A Sherman, John Godwin, Shirin Ali, Cecilia Tomori, Charles L Bennett.   

Abstract

Ensuring the safety of the blood supply connects politics and science. The business and service sectors share responsibility for the collection and processing of blood donations, and government agencies perform regulatory and surveillance roles. The onset of the AIDS epidemic has challenged the interface among these systems, leading to widespread fears about compromised safety of the blood supply. Because of public concern about blood-supply decisions made in the 1980s, developed countries in the 1990s established reimbursement programs for persons with transfusion-acquired viral infections from blood or blood products, adopted diagnostic tests and procedures that improved the safety of the blood supply, and held criminal judicial investigations of government officials and industry leaders accused of delaying implementation of potential blood-safety measures. In contrast, developing countries continue to struggle with blood-supply safety issues. This paper summarizes the current status of these safety concerns in developed countries, where viral transmission from contaminated blood or blood products is extremely rare, and in developing countries, where up to 10% of HIV infections result from transfusion of blood or blood products.

Entities:  

Mesh:

Year:  2002        PMID: 11848729     DOI: 10.7326/0003-4819-136-4-200202190-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Geographic location of commercial plasma donation clinics in the United States, 1980-1995.

Authors:  Robert C James; Cameron A Mustard
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

Review 2.  Safety of the blood supply in Latin America.

Authors:  Gabriel A Schmunis; Jose R Cruz
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 3.  Today's challenges in pharmacovigilance: what can we learn from epoetins?

Authors:  Hans C Ebbers; Aukje K Mantel-Teeuwisse; Ellen H M Moors; Huub Schellekens; Hubert G Leufkens
Journal:  Drug Saf       Date:  2011-04-01       Impact factor: 5.606

4.  Use of seroconversion panels to estimate delay in detection of anti-human immunodeficiency virus antibodies by enzyme-linked immunosorbent assay of pooled compared to singleton serum samples.

Authors:  Lena Novack; Noya Galai; Arieh Yaari; Mordechai Orgel; Eilat Shinar; Batia Sarov
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 5.  Translation of biomedical prevention strategies for HIV: prospects and pitfalls.

Authors:  Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

6.  Patient blood management in Europe.

Authors:  A Shander; H Van Aken; M J Colomina; H Gombotz; A Hofmann; R Krauspe; S Lasocki; T Richards; R Slappendel; D R Spahn
Journal:  Br J Anaesth       Date:  2012-05-24       Impact factor: 9.166

7.  Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?

Authors:  Andrew J W Samis
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

8.  Making patient blood management the new norm(al) as experienced by implementors in diverse countries.

Authors:  Axel Hofmann; Donat R Spahn; Anke-Peggy Holtorf
Journal:  BMC Health Serv Res       Date:  2021-07-02       Impact factor: 2.655

9.  The prevalence of HTLV-1 and its Co-Infection with HCV, HBV and HIV in Hemophilic patients.

Authors:  Masood Ziaee; Mohammad Hassan Namaei; Ghodseh Azarkar
Journal:  Pak J Med Sci       Date:  2015 Sep-Oct       Impact factor: 1.088

10.  Medical decision making and risky choices: psychological and medicolegal consequences of HIV and HCV contamination of blood products.

Authors:  S Riva; S Del Sordo; U Genovese; G Pravettoni
Journal:  HIV AIDS (Auckl)       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.